参考文献/References:
[1] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74:229-263.
[2]Ganesan P,Kulik LM.Hepatocellular carcinoma:new developments[J].Clin Liver Dis,2023,27:85-102.
[3]Reig M,Forner A,Rimola J,et al.BCLC strategy for prognosis prediction and treatment recommendation:The 2022 update[J].J Hepatol,2022,76:681-693.
[4]Park JW,Chen M,Colombo M,et al.Global patterns of hepatocellular carcinoma management from diagnosis to death:the BRIDGE Study[J].Liver Int,2015,35:2155-2166.
[5]仲斌演,滕皋军.中晚期肝细胞癌以TACE为基础的综合治疗[J].介入放射学杂志,2025,34:1-4.
Zhong BY,Teng GJ.Comprehensive treatment based on TACE for intermediate and advanced hepatocellular carcinoma[J].J Interv Radiol,2025,34:1-4.
[6]Cheng AL,Qin S,Ikeda M,et al.Updated efficacy and safety data from IMbrave150:Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J].J Hepatol,2022,76:862-873.
[7]Ren Z,Xu J,Bai Y,et al.Sintilimab plus a bevacizumab biosimilar(IBI305)versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32):a randomised,open-label,phase 2-3 study[J].Lancet Oncol,2021,22:977-990.
[8]Qin S,Chan SL,Gu S,et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310):a randomised,open-label,international phase 3 study[J].Lancet,2023,402:1133-1146.
[9]Zhu HD,Li HL,Huang MS,et al.Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)[J].Signal Transduct Target Ther,2023,8:58.
[10]Jin ZC,Zhong BY,Chen JJ,et al.Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC(CHANCE2211):a propensity score matching study[J].Eur Radiol,2023,33:8669-8681.
[11]Jin ZC,Chen JJ,Zhu XL,et al.Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma(CHANCE2201):a target trial emulation study[J].E Clinical Medicine,2024,72:102622.
[12]Sangro B,Kudo M,Erinjeri JP,et al.Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma(EMERALD-1):a multiregional,randomised,double-blind,placebo-controlled,phase 3 study[J].Lancet,2025,405:216-232.
[13]Llovet J,Finn RS,Ren Z,et al.LBA3 Transarterial chemoembolization(TACE)with or without lenvatinib(len)+ pembrolizumab(pembro)for intermediate-stage hepatocellular carcinoma(HCC):Phase Ⅲ LEAP-012 study[J].Ann Oncol,2024,35:S1229.
[14]Davis AA,Patel VG.The role of PD-L1 expression as a predictive biomarker:an analysis of all US Food and Drug Administration(FDA)approvals of immune checkpoint inhibitors[J].J Immunother Cancer,2019,7:278.
[15]Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12:252-264.
[16]Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372:2018-2028.
[17]Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375:1823-1833.
[18]Taube JM,Klein A,Brahmer JR,et al.Association of PD-1,PD-1 ligands,and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J].Clin Cancer Res,2014,20:5064-5074.
[19]Doroshow DB,Bhalla S,Beasley MB,et al.PD-L1 as a biomarker of response to immune-checkpoint inhibitors[J].Nat Rev Clin Oncol,2021,18:345-362.
[20]Hu X,Deng X,Xie J,et al.Heterogeneous PD-L1 expression in metastases impacts immunotherapy response[J].EBioMedicine,2023,97:104816.
[21]Hao X,Zheng Z,Liu H,et al.Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing[J].Redox Biol,2022,56:102463.
[22]Xie M,Lin Z,Ji X,et al.FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2[J].J Hepatol,2023,79:109-125.
[23]Riley TP,Keller G,Smith AR,et al.Structure based prediction of neoantigen immunogenicity[J].Front Immunol,2019,10:2047.
[24]Zhu AX,Abbas AR,de Galarreta MR,et al.Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma[J].Nat Med,2022,28:1599-1611.
[25]Zhai XY,Xia ZJ,Du G,et al.LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance[J].Genes Dis,2023,10:2082-2096.
[26]Chabanon RM,Pedrero M,Lefebvre C,et al.Mutational landscape and sensitivity to immune checkpoint blockers[J].Clin Cancer Res,2016,22:4309-4321.
[27]He Y,Lu M,Che J,et al.Biomarkers and future perspectives for hepatocellular carcinoma immunotherapy[J].Front Oncol,2021,11:716844.
[28]Craig AJ,von Felden J,Garcia-Lezana T,et al.Tumour evolution in hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol,2020,17:139-152.
[29]Vogel A,Meyer T,Sapisochin G,et al.Hepatocellular carcinoma[J].Lancet,2022,400:1345-1362.
[30]崔涵姝,刘 斌.应用改善病情抗风湿药物治疗骨关节炎之争[J].协和医学杂志,2025,16:13-18.
Cui HS,Liu B.Controversy about management of osteoarthritis with disease-modifying anti-rheumatic drugs[J].J Peking Union Med Coll Hosp,2025,16:13-18.
[31]Lambin P,Rios-Velazquez E,Leijenaar R,et al.Radiomics:extracting more information from medical images using advanced feature analysis[J].Eur J Cancer,2012,48:441-446.
[32]Zhang YP,Zhang XY,Cheng YT,et al.Artificial intelligence-driven radiomics study in cancer:the role of feature engineering and modeling[J].Mil Med Res,2023,10:22.
[33]Feng S,Wang J,Wang L,et al.Current status and analysis of machine learning in hepatocellular carcinoma[J].J Clin Transl Hepatol,2023,11:1184-1191.
[34]Lambin P,Leijenaar R,Deist TM,et al.Radiomics:the bridge between medical imaging and personalized medicine[J].Nat Rev Clin Oncol,2017,14:749-762.
[35]Kang WD,Tang PY,Luo YG,et al.Multiparametric MRI-based machine learning radiomics for predicting treatment response to transarterial chemoembolization combined with targeted and immunotherapy in unresectable hepatocellular carcinoma:a multicenter study[J].Acad Radiol,2024:S1076-6332(24)00825-00820.
[36]Hua YL,Sun ZX,Xiao YX,et al.Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy[J].J Immunother Cancer,2024,12:e008953.
[37]Ivanics T,Salinas-Miranda E,Abreu P,et al.A pre-TACE radiomics model to predict HCC progression and recurrence in liver transplantation:a pilot study on a novel biomarker[J].Transplantation,2021,105:2435-2444.
[38]Liu QP,Yang KL,Xu X,et al.Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoemboli-zation:a two-center collaborative study[J].Abdom Radiol(NY),2022,47:651-663.
[39]Fang S,Lai L,Zhu J,et al.A radiomics signature-based nomogram to predict the progression-free survival of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization plus radiofrequency ablation[J].Front Mol Biosci,2021,8:662366.
[40]Luo J,Huang Z,Wang M,et al.Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy[J].BMC Gastroenterol,2022,22:108.
[41]Sheen H,Kim JS,Lee JK,et al.A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion[J].Abdom Radiol(NY),2021,46:2839-2849.
[42]de Aguiar RB,de Moraes JZ.Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors[J].Front Immunol,2019,10:1023.
[43]胡灵溪,李 妹,付艺伟,等.血清血管内皮生长因子对肝动脉化疗栓塞单独/联合靶免治疗在中晚期肝癌临床疗效中的评估价值[J].中国全科医学,2024,27:4033-4039.
Hu LX,Li M,Fu YW,et al.Evaluation value of serum vascular endothelial growth factor in the clinical efficacy of transarterial chemoembolization alone/combined with targeted and immunotherapy for intermediate and advanced hepatocellular carcinoma[J].Chin Gen Pract,2024,27:4033-4039.
[44]王 刚,齐金蕾,刘馨雅,等.中国阿尔茨海默病报告2024[J].诊断学理论与实践,2024,23:219-256.
Wang G,Qi JL,Liu XY,et al.China Alzheimer Report 2024[J].J Diagn Concepts Pract,2024,23:219-256.
[45]张永红,沈预程,陆滢滢,等.HIF-1、AFP-L3和sPD-L1对原发性肝癌患者病情和TACE联合索拉非尼疗效的评估价值[J].肝脏,2024,29:1368-1373.
Zhang YH,Shen YC,Lu YY,et al.Evaluation value of HIF-1,AFP-L3 and sPD-L1 in patients with primary liver cancer and the efficacy of TACE combined with sorafenib[J].Chin Hepatol,2024,29:1368-1373.
[46]闫 雷,芦亚楠,李 红,等.卡瑞利珠单抗联合TACE治疗晚期原发性肝癌的疗效及其对血清T淋巴细胞、AFP-L3等的影响[J].临床和实验医学杂志,2024,23:1490-1493.
Yan L,Lu YN,Li H,et al.Efficacy of combination therapy with Carolizumab and TACE in the treatment of advanced hepatocellular carcinoma and its effects on serum T lymphocytes,AFP-L3[J].J Clin Exp Med,2024,23:1490-1493.
[47]Yang Y,Li G,Lu Z,et al.Progression of prothrombin induced by vitamin K absence-Ⅱ in hepatocellular carcinoma[J].Front Oncol,2021,11:726213.
[48]Ringelhan M,Pfister D,O'Connor T,et al.The immunology of hepatocellular carcinoma[J].Nat Immunol,2018,19:222-232.
[49]Templeton AJ,McNamara MG,Seruga B,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis[J].J Natl Cancer Inst,2014,106:dju124.
[50]Zheng X,Qian K.Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma[J].Anticancer Drugs,2023,34:775-782.
[51]Tan JZ,Fan WZ,Liu T,et al.TREM2(+)macrophages suppress CD8(+)T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J].J Hepatol,2023,79:126-140.
[52]Yang F,Xu GL,Huang JT,et al.Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma:efficacy and systemic immune response[J].Front Immunol,2022,13:847601.
[53]Demirtas CO,D'Alessio A,Rimassa L,et al.ALBI grade:evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma[J].JHEP Rep,2021,3:100347.
[54]李佳清,徐啸阳,胡泽鑫,等.改良白蛋白-胆红素分级对经导管动脉化疗栓塞术联合免疫及抗血管生成药物治疗的Child-Pugh A级不可切除肝细胞癌患者预后的预测价值[J].临床肝胆病杂志,2024,40:2450-2456.
Li JQ,Xu XY,Hu ZX,et al.Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs[J].J Clin Hepatol,2024,40:2450-2456.
[55]Scheiner B,Pomej K,Kirstein MM,et al.Prognosis of patients with hepatocellular carcinoma treated with immunotherapy-development and validation of the CRAFITY score[J].J Hepatol,2022,76:353-363.
[56]Hu ZX,Xu XY,Wang Z,et al.Prognosis prediction of CRAFITY score in HCC undergoing TACE combined with PD-(L)1 inhibitors and molecular targeted therapy[J].J Hepatocell Carcinoma,2023,10:2073-2082.
[57]Cabibbo G,Celsa C,Enea M,et al.Optimizing sequential systemic therapies for advanced hepatocellular carcinoma:a decision analysis[J].Cancers(Basel),2020,12:2132.
[58]Schwabe RF,Greten TF.Gut microbiome in HCC-Mechanisms,diagnosis and therapy[J].J Hepatol,2020,72:230-238.
[59]Xie G,Wang X,Huang F,et al.Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis[J].Int J Cancer,2016,139:1764-1775.
[60]Routy B,Le Chatelier E,Derosa L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science,2018,359:91-97.
(收稿日期:2025-02-18)
(本文编辑:新 宇)
相似文献/References:
[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(12):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(12):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(12):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(12):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(12):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[8]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(12):185.
[9]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Intervent Med,2009,(12):437.
[10]王惠文,刘瑞宝,刘 岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Intervent Med,2011,(12):621.